Pankit Vachhani, MD, is an associate professor of medicine and associate scientist of experimental therapeutics at the University of Alabama at Birmingham.

Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Presented by Dr. Pankit Vachhani, this updated analysis of the PIONEER trial demonstrated that long-term treatment with avapritinib led to sustained symptom relief, improved quality of life, and maintained a favorable safety profile over approximately 3 years in patients with indolent systemic mastocytosis.